|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.3020 - 0.3170|
|52 Week Range||0.2920 - 0.8080|
|Beta (3Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.25|
Novacyt SA’s (EPA:ALNOV): Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company’s loss has recently broadened since it announced a -€5m loss in the full Read More...
AIM: NCYT), an international specialist in clinical diagnostics, announces the conversion of the €4.0m unsecured, anti-dilutive debt facility (the “Advance”) from a French institutional investor, into an unsecured Convertible Bond (the “Convertible Bond”) further to the announcement on 30 May 2018. The Convertible Bond will be issued on 30 June 2018 following the successful outcome of the Extraordinary General Meeting (EGM) on 11 June 2018, which granted the Company sufficient authorities to issue equity. The Convertible Bond will be issued in a single tranche with a maturity of three years and bears an annual interest rate of 7.4%.
Novacyt Société Anonyme’s (ENXTPA:ALNOV): Novacyt Société Anonyme develops and sells diagnostic products for cancer and infectious diseases. The €25.56M market-cap company announced a latest loss of -€5.44M on 31 DecemberRead More...
Examining Novacyt Société Anonyme’s (ENXTPA:ALNOV) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...